Last reviewed 2026-04-22 · How we verify

LENOGRASTIM (GRANOGYTE 34)

Lenograstim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil precursor cells in bone marrow.

Lenograstim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil precursor cells in bone marrow. Used for Chemotherapy-induced neutropenia, Bone marrow transplantation support, Severe congenital neutropenia.

At a glance

Mechanism of action

Lenograstim binds to G-CSF receptors on hematopoietic progenitor cells, promoting their maturation into functional neutrophils and releasing them into circulation. This increases neutrophil counts and enhances their antimicrobial activity, helping to prevent or treat neutropenia and associated infections in patients undergoing chemotherapy or bone marrow transplantation.

Approved indications

• Chemotherapy-induced neutropenia
• Bone marrow transplantation support
• Severe congenital neutropenia
• Mobilization of peripheral blood progenitor cells for autologous transplantation

Common side effects

• Bone pain
• Headache
• Fatigue
• Fever
• Injection site reactions
• Splenomegaly

Key clinical trials

• A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• LENOGRASTIM (GRANOGYTE 34) CI brief — competitive landscape report
• LENOGRASTIM (GRANOGYTE 34) updates RSS · CI watch RSS
• Sanofi portfolio CI